RCC1 and BTB domain containing protein 2Genealiases: CHC1L · RLG
Q-omics provides the consensus-scored RCBTB2 profile across patient tissues and cancer cell-line models. RCBTB2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RCBTB2 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, RCBTB2 protein abundance shows 21,977 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where RCBTB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RCBTB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RCBTB2 survival associations across molecular data types. RCBTB2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RCBTB2 RNA expression–survival associations across cancer types. High RCBTB2 expression shows unfavorable associations in LGG, but favorable associations in KIRC, HNSC, KIRP, LUAD and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RCBTB2 RNA expression.
This table summarizes RCBTB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RCBTB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RCBTB2 shows lower tumor expression in KICH, THCA, BLCA, LUAD and UCEC and higher tumor expression in KIRC. The KICH box plot shows higher RCBTB2 RNA expression in normal versus tumor tissue (log2 FC = −2.045, t-test p < 0.001).
This table shows molecular features associated with RCBTB2 in patient tissues and cancer cell lines. In patient samples, RCBTB2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RCBTB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
